Press Releases Johnson & Johnson Mexican S.E.

Equities

JNJ *

US4781601046

End-of-day quote Mexican S.E. Other stock markets 18:00:00 2024-06-06 EDT			5-day change	1st Jan Change
2,709 ^MXN	+3.40%		+8.80%	+2.39%

12:18am	Top law firms in US opioid lawsuits to get hundreds of millions in fees	RE
06-07	J&J-backed Rapport Therapeutics shares debut nearly 6% higher	RE

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Johnson & Johnson : DePuy Synthes Receives 510(k) FDA Clearance of the VELYS™ Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty Procedures	06-07	PU
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	06-05	AQ
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results	06-04	BU
Johnson & Johnson : showcases innovation and leadership in rheumatology at EULAR 2024 Congress	06-04	PU
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	06-04	AQ
Johnson & Johnson Completes Acquisition of Shockwave Medical	06-03	AQ
Johnson & Johnson - First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration	06-03	AQ
Johnson & Johnson Executive Vice President, William N. Hait, M.D., Ph.D., to Retire, Effective September 2024	05-31	AQ
Johnson & Johnson Completes Acquisition of Shockwave Medical	05-31	BU
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Press Release	05-29	PU
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	05-29	AQ
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Transcript	05-28	PU
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis	05-28	AQ
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis	05-28	BU
Johnson & Johnson: Meet a nurse who leads clinical trials to find innovative cancer therapies	05-24	AQ
Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA	05-24	PU
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation	05-22	BU
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences	05-22	AQ
TREMFYA (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission	05-21	AQ
Novel biologic could offer ulcerative colitis symptomatic remission	05-21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm